Head to Head Review: Novonesis A/S (NVZMY) vs. Its Peers

Novonesis A/S (OTC:NVZMY) is one of 300 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it contrast to its rivals? We will compare Novonesis A/S to related businesses based on the strength of its profitability, institutional ownership, analyst recommendations, risk, valuation, earnings and dividends.

Profitability

This table compares Novonesis A/S and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Novonesis A/S	N/A	N/A	N/A
Novonesis A/S Competitors	-2,185.76%	-161.46%	-40.62%

Earnings & Valuation

This table compares Novonesis A/S and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Novonesis A/S	$2.60 billion	$439.08 million	35.48
Novonesis A/S Competitors	$597.47 million	-$69.94 million	-1.17

Novonesis A/S has higher revenue and earnings than its rivals. Novonesis A/S is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of current ratings for Novonesis A/S and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novonesis A/S	1	0	0	0	1.00
Novonesis A/S Competitors	1872	5289	13659	288	2.59

As a group, “Biological products, except diagnostic” companies have a potential upside of 85.25%. Given Novonesis A/S’s rivals stronger consensus rating and higher possible upside, analysts clearly believe Novonesis A/S has less favorable growth aspects than its rivals.

Insider and Institutional Ownership

0.0% of Novonesis A/S shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 15.7% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Novonesis A/S has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500. Comparatively, Novonesis A/S’s rivals have a beta of 1.03, suggesting that their average stock price is 3% more volatile than the S&P 500.

Dividends

Novonesis A/S pays an annual dividend of $0.35 per share and has a dividend yield of 0.6%. Novonesis A/S pays out 22.2% of its earnings in the form of a dividend. As a group, “Biological products, except diagnostic” companies pay a dividend yield of 2.8% and pay out 229.5% of their earnings in the form of a dividend.

Summary

Novonesis A/S rivals beat Novonesis A/S on 8 of the 15 factors compared.

Novonesis A/S Company Profile

Novonesis A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services. In addition, the company provides dishwashing, softener, microbial and medical cleaning services. Further, it provides corn, cotton, forages, peanuts, pulses, soybeans, wheat, small grains, bioyield, and biocontrol solutions; warm water species, recirculating aquaculture system; animal health and nutrition solutions; fiber modification, bleach boosting, deposit control, and starch modification solutions. Additionally, the company provides carbon capture, leather and textiles solutions; enzyme solutions, including corn and wheat separation, liquefaction, saccharification, filtration, isomerization, maltose, and specialties solutions; warm water species and recirculating aquaculture system solutions; human health solutions, comprising brain, oral, protective and immune, and gastrointestinal health solutions; ethanol, biodiesel, renewable diesel, education, wastewater, and sewage sludge, and renewable diesel solutions; agriculture and industry, biogas food waste, food waste, biocatalysis, cell culture, diagnostics, enzyme, and biogas solutions. Furthermore, it provides lipases, proteases, oxidoreductases, and carbohydrases. Novonesis A/S was founded in 1925 and is based in Bagsvaerd, Denmark.